Efficacy and safety of chemotherapy combined with different doses of IL-2 maintenance therapies for acute myeloid leukemia: A protocol for a Bayesian network meta-analysis.

Medicine
Xuewei YinRuirong Xu

Abstract

Acute myeloid leukemia (AML) is the most common malignant tumor of the hematopoietic system, which seriously threatens the lives of patients. Most AML patients have acute onset, severe condition, and poor prognosis. The present study aimed to comprehensively evaluate the effectiveness and safety of chemotherapy combined with different doses of interleukin-2 (IL-2) maintenance treatments in AML by Bayesian network meta-analysis (NMA). From its inception until October 2021, we will search PubMed, Cochrane Library, CNKI, Embase, and other databases to comprehensively collect randomized controlled trials (RCTs) of chemotherapy combined with different doses of IL-2 maintenance therapies for AML. Two independent researchers will complete the literature screening and data extraction according to the inclusion and exclusion criteria, and then independently conduct a bias risk assessment of all the evidence. Bayesian NMA was used to evaluate all the evidence comprehensively. Use STATA16.0 and WinBUGS1.4.3 software to process and analyze all data, and classify the quality of evidence in NMA according to grading of recommendations assessment, development, and evaluation . The study will evaluate the efficacy and safety of chemotherapy com...Continue Reading

References

Jul 2, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Maria R BaerRichard A Larson
Jan 6, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Cecile PautasSylvie Castaigne
Mar 10, 2010·Statistics in Medicine·S DiasA E Ades
Feb 15, 2013·Experimental and Therapeutic Medicine·Sheng LuoShenmeng Gao
Sep 26, 2014·BMJ : British Medical Journal·Milo A PuhanUNKNOWN GRADE Working Group
Oct 17, 2014·Journal of Biopharmaceutical Statistics·Divan Aristo Burger, Robert Schall
Jan 4, 2015·BMJ : British Medical Journal·Larissa ShamseerUNKNOWN PRISMA-P Group
Sep 12, 2015·Biometrical Journal. Biometrische Zeitschrift·Rafael Sauter, Leonhard Held
Jul 12, 2017·Journal of Translational Medicine·Meghali GoswamiChristopher S Hourigan
Jun 4, 2018·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Hideaki KatoUNKNOWN Japan Adult Leukemia Study Group
Oct 26, 2018·Research Synthesis Methods·Isabelle Albert, David Makowski

❮ Previous
Next ❯

Software Mentioned

Cochrane Collaboration
STATA16
EndNoteX9
GRADE
WinBUGS1

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.